On Joe Allen’s claims that former Senators can provide authoritative statements on legislative intent decades after leaving office, especially when they worked as lobbyists

A recent blog published in IPWatchdog expresses outrage at accurate observations made by James Love, director of Knowledge Ecology International (KEI), that former Senators Birch Bayh and Bob Dole acquired financial ties to the pharmaceutical industry between the enactment of… Continue Reading

KEI Comments on NIH Proposed Exclusive License to Iovance for Cancer Cell Therapy

On Friday March 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Engineered Tumor Infiltrating Lymphocytes for Cancer Therapy” (86 FR 11548). The technology is… Continue Reading

Canada based Biolyse Pharma Seeks to Manufacture COVID-19 Vaccines for Low-Income Countries, may test Canada’s compulsory licensing for export law

On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading

KEI Comments on NIH Exclusive Licenses to Kyverna on CAR T therapy

(Update: The NIH provided responses to our comments on April 5, 2021 – 86 FR 10092 Response and 86 FR 10081 Response) On Friday March 5, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institute of Health (NIH)… Continue Reading

NIST Proposed Revisions to Bayh-Dole Act Regulations

New: Biden White House Executive Order opposes change in Bayh-Dole March-In regulations. (KEI has an email list to discuss this issue here: http://lists.keionline.org/mailman/listinfo/bayh-dole-regulations_lists.keionline.org) The Department of Commerce’s National Institute of Standards and Technology (NIST) published on January 4, 2021, a… Continue Reading

KEI Comments to NIH Proposed Exclusive License to Ziopharm for Cell Therapy Cancer Treatment

On February 9, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer” to Ziopharm Oncology, Inc. (Ziopharm). The… Continue Reading

KEI Comments on NIH Exclusive License to Canadian Firm EpifiZa

On Tuesday February 9, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Certain Fusion Proteins and Their Use for the Treatment… Continue Reading